BeiGene looks at new partnerships, with a full cancer pipeline and growing...
Less than a year after the end of a PD-1 deal with Novartis, BeiGene is looking at new partnerships that could bring in new assets it could develop or commercialize, or out-license some of its...
View ArticleClik here to view.
Aiming to decentralize CAR-T manufacturing, Galapagos partners with largest...
Galapagos is teaming up with the US’s largest blood supply group to try to establish a nationwide network of decentralized CAR-T manufacturing. The partnership with Blood Centers of America, or BCA,...
View ArticleRoche teases 'encouraging' Phase 1 data for weight loss drug from $2.7B...
Roche offered a glimpse at promising early efficacy data on Thursday morning from a GLP-1/GIP agonist it obtained as part of its $2.7 billion acquisition of Carmot Therapeutics. In a Phase 1 trial...
View ArticleGastroparesis biotech CinDome secures $40M for path to pivotal trial
A gastroparesis biotech from the creator of CinCor Pharma, the hypertension biotech bought by AstraZeneca for $1.8 billion last year, has raised an additional $40 million to get through Phase 2 and...
View ArticleClik here to view.
GSK, UK government budget £130M to fight global antimicrobial resistance
GSK and the UK government have pledged £130 million ($165 million) to tackle antimicrobial resistance (AMR) at home and abroad by improving access to existing medicines and diagnostic tools. GSK said...
View ArticleLilly touts topline late-phase data for once-weekly insulin in race to enter...
As Novo Nordisk stares down an FDA adcomm later this month to discuss its once-weekly insulin, Eli Lilly is working on its own, sharing positive topline data from two Phase 3 studies for its insulin...
View ArticleClik here to view.
J&J makes small I&I acquisition to enter competitive IL-13, TSLP arena
Johnson & Johnson said Thursday it will pay $850 million in cash for Proteologix, a relatively unknown private biotech working on treatments for immune-mediated diseases, including the crowded...
View ArticleAstraZeneca's successor to Covid blockbuster Evusheld succeeds in Phase 3 trial
AstraZeneca’s latest antibody to prevent Covid-19 hit on both of its primary endpoints in a large Phase 3 trial, the UK company said Thursday. The preventive treatment known as sipavibart, which will...
View ArticleMonte Rosa’s $100M offering; Alexion to hand back preclinical program to...
Plus, news about First Wave BioPharma: Monte Rosa’s $100M offering: The molecular glue degrader biotech priced the offering at $4.70 per share $GLUE and expects it to close on May 20. At the end of...
View ArticleClik here to view.
Biogen and Ionis abandon ALS drug after disappointing early-stage trial
Biogen and Ionis are dropping an experimental treatment for amyotrophic lateral sclerosis, or ALS, a neurodegenerative disease in which people lose muscle control over time. The decision was based on...
View ArticleClik here to view.
Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
Pfizer and Arvinas’ targeted protein degrader plus Ibrance has shown promising efficacy in breast cancer patients in updated data from an early-stage trial, raising anticipation for a pair of ongoing...
View ArticleWuXi Biologics pauses Massachusetts build; Novo Holdings nabs majority stake...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. WuXi Biologics has “temporarily paused” the construction of its new...
View ArticleBiogen CEO Viehbacher undaunted by Lilly's impending Alzheimer's therapy,...
NEW YORK — Facing a challenging launch for the Alzheimer’s drug Leqembi, Biogen CEO Chris Viehbacher said he would welcome competition from other companies, including Eli Lilly, which is aiming for an...
View ArticleBristol Myers wins accelerated approval for another blood cancer for...
Just two months after earning another approval for its blockbuster blood cancer drug Breyanzi, Bristol Myers Squibb can add an accelerated approval to the list, this time in the third-line setting for...
View ArticleClik here to view.
House panel advances bills targeting rare disease, priority review vouchers
WASHINGTON — Lawmakers advanced the reauthorization of an FDA program designed to stimulate the development of treatments for pediatric rare diseases, despite some opposition from Democrat lawmakers....
View ArticleBain, Atlas, RTW back new biotech developing obesity drugs with $400M
A new obesity biotech has entered the field — and it has $400 million from well-known life sciences investors to test investigational GLP-1 and GIP candidates licensed from Jiangsu Hengrui...
View ArticleRoche was in 'advanced' talks to out-license its Angelman syndrome drug, but...
Roche is back to square one for finding a partner to carry forward its culled Angelman syndrome drug. Last June, the Swiss pharma had started a search for a partner after stopping clinical testing of...
View ArticlePharma is rethinking how it interacts with patients after Eli Lilly ripped up...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) More pharma companies are considering taking a tip from Eli Lilly and offering their drugs directly to...
View ArticleGSK plans to sell off remaining stake in consumer spinout Haleon
British drugmaker GSK will sell off the rest of its share in Haleon after slowly selling off multibillion-dollar pieces of its ownership in the consumer company. The sale of the final 4.2% stake in...
View ArticleClik here to view.
FDA approves Amgen’s T cell engager in aggressive form of lung cancer
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases....
View Article